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ABSTRACT 
Simmons, Stacy. M.S. Department of Biochemistry and Molecular Biology, Wright State 
University 2019. Genotyping for Response to Physical Training  
 
Understanding the inter-individual variability in physical fitness performance has been the focus 
of scientific research for decades especially in the United States military. Injury and physical 
inadequacy cost the U.S military millions of dollars every year. The project PHITE (Precision High 
Intensity Training through Epigenetics) was funded to investigate this personal complex trait by 
combing the genetic and epigenetic (non-shared environmental factors) contributions into a 
single model for physical training response. This project is set up as having 150 male and female 
recruits between the ages of 18-27 years old. Each participant is randomly put blind into either 
a high intensity or moderate intensity (group A or group B) 12-week training program. The 
training response was measured by various means including % change in chest press, lat pull, 
VO2max, among others and muscle biopsies and blood samples were collected regularly. The 
genetic contribution was examined by using Taqman qPCR genotyping for common single 
nucleotide polymorphisms (SNP) found in the literature to contribute to physical performance. 
By combining the genotyping data with the training response data, it was hypothesized that the 
training response would be different depending on the training group assigned and that 
genotype can be used to develop a predictor for training response. There were two main aims 
that were investigated for this hypothesis: the performance difference between the high and 
moderate intensity; and whether genotype could be used as a predictor of this training 
response. Individual training responses and overall performance in each training group was 
investigated using ANOVA analysis. It was determined that there wasn’t a significant difference 
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in individual training responses for each group, but overall performance in group B was 
significantly higher than group A (p=0.0059). Five different analyses were used to investigate 
whether genotype could be used as a predictor for training response: ANOVA of beneficial 
allele score, ANOVA of performance score, Fisher’s exact test, ANOVA of individual 
performance results, and GWAS analysis. 16 SNPs were found to be associated with either 
individual training responses or overall performance response. These results support the 
importance of considering genotype in any model of physical training response. 
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A. Physical Fitness in the Military 
 
Physical fitness is determined by numerous genes and epigenetic modifications to those genes 
and many previous studies have used genetic markers known as single nucleotide 
polymorphisms (SNPs) to study the differences in physical fitness among individuals (Piotr 
Gronek, 2013). The challenge with this kind of study is only 66% of variance in physical fitness 
can be explained with genetic markers; the other 34% is from non-shared environmental 
factors that produce epigenetic variation (Bamman & Broderick, 2018). Inter-individual 
variability in physical fitness has always been a focus in scientific research specifically in a 
military setting. Injury and physical inadequacy lead to a huge challenge when it comes to 
training candidates for special missions. In one United States Air Force Combat Rescue Officer 
Training, 70% of washouts occurred in the physically intensive development part of the course. 
It has also been reported that 20% of all program washouts occur during day 5 pass/fail physical 
fitness test (Chappelle, 2015). The washout rate /high injury rate cost the military millions of 
dollars every year, therefore, being able to predict response to various physical training 
protocols, assess peak performance, and avoiding overtraining and injury is a necessity 
(Bamman & Broderick, 2018).  
The project called PHITE (Precision High Intensity Training through Epigenetics) is a multi-year 
project investigating relevant genotype contribution and the changes in DNA methylation, 
chromatin/histones, miRNA, and nuclear transcription factors to changes in performance from 
physical training. The focus of this thesis is to determine the genetic contribution to physical 
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fitness in the first 42 completers of the PHITE training group. By combining the genotyping data 
with the training response data, it was hypothesized that the training response would be 
different depending on the training group assigned and that genotype can be used to develop a 
predictor for training response. There were two main aims that were investigated for this 
hypothesis: the performance difference between the high and moderate intensity; and whether 
genotype could be used as a predictor of this training response. 
B. Genotyping Using Single Nucleotide Polymorphisms  
 
As previously mentioned, single nucleotide polymorphisms or SNPs are common genetic 
markers that occur naturally and are the most common type of genetic variation among 
individuals. SNPs are widely used as genetic markers for a variety of studies and are great tools 
to use to determine genetic contribution for physical fitness. Polymorphisms potentially 
associated with physical fitness and/or response to physical training were gathered from a 
review of the literature. Many SNPs come from Bray et al. 2009 (Bray MS1, 2009) , Yoo et al. 
2016 (Yoo J, 2016), Timmons et al. 2010 (Timmons, 2009), and Rankinen et al. 2012 (Rankinen T 
S. Y., 2012), as well as many other studies as indicated in Table S4- S10. During this review, SNPs 
were excluded if they: 
• Came from a study with an N of 1, or only in a single family 
• Were associated with severe congenital phenotypes 
• Were associated with diseases such as ALS, cystic fibrosis, or other diseases that directly 
impact physical capability 
• Were discounted by follow up studies  
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• Had an unknown minor allele frequency 
An additional ten SNPs were chosen within the genes encoding proteins responsible for 
epigenetic modification. While these had not been demonstrated to play roles in physical 
performance, they are related to the epigenetic portion of PHITE; several of these have been 
demonstrated to affect protein function and therefore global DNA methylation (e.g. rs2276731 
in FTHFD (Min-Ae Song, 2016) or rs1801131 and rs1801133 in MTHFR (Castro, 2004). A total of 
181 SNPs and one base pair insertion/deletion were chosen and classified based on what 
physical attributes each affect in association with physical fitness. The beneficial alleles were 
also determined during this literature review and are indicated in Table S4-10. In some cases, 
the heterozygous genotype is indicated instead of a specific allele, this is due to either allele 
being beneficial to physical training response. Table 1 shows a summary of all the SNPs chosen 
for this study.  
Table 1: Summary of SNPs Chosen for PHITE 
SNPs Associated with  N= 
Aerobic Capacity/Endurance/VO2max 35 
Physical Strength/Response to Training/Muscle Volume  28 
Blood Pressure/Cardiovascular/Heart Rate 69 
Increased BMI/Obesity/Diabetes 30 
Endurance/Strength 2 
Other (Bone Density/Height/Metabolism) 8 
Epigenetic Modifiers  10 
Total 182 
 
1. Aerobic Capacity/Endurance/VO2max 
 
One of the major contributing factors to physical fitness is aerobic capacity. Aerobic capacity is 
most universally measured by using the maximal rate of oxygen consumption (VO2max). 
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VO2max is defined as the oxygen uptake attained during maximal exercise intensity that could 
not be increased despite increase in exercise load which defines the limits of the 
cardiorespiratory system (Megan Hawkins, 2007). VO2max is the gold standard measure of 
aerobic endurance and cardiorespiratory fitness (Yoo J, 2016). A group of SNPs were identified 
to be associated with aerobic capacity, endurance and increases in VO2max.  
2. Physical Strength/Response to Training/Muscle Volume 
 
A large contributor to physical fitness variation is physical/muscle strength and overall response 
to physical training. Muscle strength has been measured in various studies by using peak 
muscle torque, or the maximum force applied by the muscles through a “moment arm” 
(calculation associated with the force generated by the muscle and the length of the limb or 
muscle group applying the force) and at a given angle to the joint associated (Yoo J, 2016). A 
group of SNPs were identified to be associated with physical strength, response to training, and 
muscle volume.  
3. Blood Pressure/Cardiovascular/Heart Rate 
 
Cardiovascular health is closely associated with physical fitness and ability to respond to 
physical training. It has been shown that with regular physical activity there are beneficial 
changes in cardiac function. These changes have been commonly measured using heart rate 
and blood pressure as physiological indicators of general cardiac health (Rankinen T S. Y., 2012). A 
group of SNPs were identified to be associated with physical strength, response to training, and 
muscle volume.  
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4. Increased BMI/Obesity/Diabetes 
 
Increased BMI and Obesity is associated with increased risk of diabetes, hypertension, and 
heart disease. Genetic markers have been reported to be associated with increased BMI and 
resistance to weight loss and have been found to negatively impact response to physical 
training (Jiang Y1, 2004).  
5. Endurance/Strength 
 
Most SNPs have one associated beneficial allele for physical fitness, but some SNPs variations 
both attribute to physical fitness. One of the most studied examples of this is the 
insertion/deletion in the angiotensin converting enzyme I (ACE). There is a 287-base pair 
insertion (I) or deletion (D) in intron 16 that has been strongly connected to elite performance 
in various sprint/power sports. The ACE protein is involved in the regulation of blood pressure 
by converting angiotensin I into angiotensin II, which is a potent vasoconstrictor and a muscle 
growth factor involved in overload-induced muscle hypertrophy (Ioannis D. Papadimitriou, 
2016). Studies have shown that the D allele is associated with high fiber mean cross sectional 
area, which has been associated with power/sprint oriented events, whereas the I allele is 
associated with a greater density of mitochondria, which has been associated with endurance 
oriented events (Flück M, 2019).  
Another well studied gene is ACTN3, which encodes for the sarcomere protein α-actinin-3 in 
skeletal muscle fibers. There is a change from a C to a T that changes an arginine (R) at position 
577 to a premature stop codon (X) in the ACTN3 gene. The ACTN3 protein is a structural protein 
found exclusively in the fast type II muscle fibers used during power activities. Studies have 
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shown that the R allele is associated with an increase in fast type II muscle fibers, which has 
been associated with power/sprint-oriented events, whereas the X allele is associated with an 
increase in oxidative muscle phenotype (muscle fiber types I and IIA) which are responsible for 
postural and endurance-oriented events (Ioannis D. Papadimitriou, 2016).  
6. Other (Bone Density/Height/Metabolism) 
 
There are many contributing genetic factors associated with physical fitness. SNPs associated 
with more of the obvious contributions have been discussed, including cardiovascular factors, 
muscle strength/volume, BMI/obesity, and others. There are other subtler factors associated 
with physical fitness, such as height, bone density, and metabolism. These were included in an 
attempt to cover all aspects of physical training response.  
7. Epigenetic Modifiers 
 
Along with the genetic marker contribution, epigenetics contributes to an individual’s overall 
physical fitness. Epigenetics is defined as changes in organisms caused by modification of gene 
expression rather than alteration of the genetic code itself. The proteins that modify gene 
expression are called epigenetic modifiers and include histone deacetylases, DNA methylases, 
and histone acetyltransferases. These SNPs have never been shown to be associated with 
physical performance, which is why the beneficial allele is marked n/a in Table S10, and if 
associated they could be novel candidates for physical fitness response and were also included 
to tie into the epigenetic section of the project.  
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II. MATERIALS AND METHODS 
 
A. Subjects and Training Protocol 
 
The PHITE participant protocol and recruitment is being completed by The University of 
Alabama at Birmingham. The project is set up to include 150 men and women, between the 
ages of 18-27 years old, recruited from the University of Alabama at Birmingham, which is 
located close to the Sumpter Smith Air Nation Guard Base (Birmingham, AL). Currently there 
are 42 completed participants that will be included in the results. Each participant was put at 
random into one of two 12-week training programs: moderate intensity or high intensity. These 
training groups are blind, so they are coded group A (n=22) and group B (n=20) and it is not 
known which group is which training protocol. Figure 1 shows the difference between the two 
groups and details associated with each. Peripheral blood draws and muscle biopsies were 
taken before, during and after the training protocols were completed. The blood was used for 
DNA extraction and SNP genotyping. Many physical performance parameters were tested at 
defined intervals, including before and after the 12 weeks. For all the analysis, the change from 
0 to 12 weeks was used for each performance parameter. Table 2 contains the 16 physical 
performance parameters used during the analysis of the first 42 completers.  
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Figure 1: The Moderate and High Intensity Training Protocols 
 
Differences in the two training groups (group A and group B); Right side shows-High 
Intesity, Left side-Moderate Intesity 
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Table 2: Physical Performance Parameters (% Change 0-12 Weeks) 
Physical Performance Test Definition 
V02peak (ml/kg/min) Numerical measurement of your body’s ability to consume oxygen 
Anaerobic Peak Power (AP) Represents the highest mechanical power generated during any 3-
5 second interval of the test 
Relative Peak Power (RP) Division of AP by body mass  
Squat  Strength exercise focused on developing lower body muscles  
Chest Press Strength exercise focused on the pectoral muscles  
Knee Extension  Resistance exercise focused on the thigh muscles  
Overhead Press Strength exercise focused on the shoulders and arms 
Lat Pull Strength exercise focused on the latissimus dorsi muscle 
Maximum Voluntary Contraction (MVC) Standardized method for the measurement of muscle strength 
Knee Peak Power (PP) Maximum power that the knee can sustain for a short time  
Vertical Jump Measurement of how high an individual can elevate off the ground 
from a standstill 
Thigh Lean Mass, Both Legs (grams)* The amount of weight on the thighs that is not fat 
Arm Lean Mass (grams* The amount of weight on the arms that is not fat 
Total Lean Mass (grams)* The amount of weight from the entire body that is not fat 
% Bodyfat* Total mass of fat divided by the total body mass of an individual 
Visceral Fat Mass (grams)* Amount of body fat that is stored within the abdominal cavity 
*Not measured as a percent change due to minimum changes from 0-12 weeks; all lean/visceral mass 
categories are change in grams and the bodyfat is the % bodyfat change. 
 
These physical parameters were used as the phenotypic data in all the analyses with separating 
groups A versus B and comparison with the genotype data.  
B. DNA Isolation and Genotyping Analysis  
 
According to manufactures’ instructions, DNA was extracted and purified from peripheral blood 
using a GeneJet Whole Blood Genomic DNA Purification Mini Kit (ThermoFisher Scientific). The 
quantity and quality of the DNA extracted was determined using a Nanodrop 
spectrophotometer. Genotyping was performed with a Taqman Assay allele discrimination 
assay using standard thermal cycling conditions as defined by the manufacturer 
(ThermoFisher). The genotypes were determined with a QuantStudio 7 Flex (Applied 
Biosystems) quantitative polymerase chain reaction (qPCR) system by measuring  
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the fluorescence signals VIC, FAM, or both in each well, which corresponds to heterozygous 
genotype. Taqman Genotyper Software (Applied Biosystems) was used for genotype 
determination and verification (Supplementary Tables 1-3 contain the raw genotyping data for 
the first 42 completers).  
C. Beneficial Allele Score   
 
Beneficial allele classifications were gathered from the literature for all relevant SNPs 
described, and a beneficial allele score was calculated (Equation 1).  
Equation 1: Example of How Beneficial Allele Score was Calculated 
SNP ID Hetero Beneficial Person 1 Person 2 Person 3 
SNP 1 A/G A A/A (2) G/G (0) G/G (0) 
SNP 2 C/T T T/T (2) C/C (0) T/T (2) 
SNP 3 G/A G G/A (1) G/G (2) G/A (1) 
Beneficial Allele Score 5 2 3 
 
In general, homozygous genotypes consisting of alleles beneficial to physical fitness were coded 
as 2, homozygous genotypes consisting of alleles harmful/neutral to physical fitness were 
coded as 0, and heterozygous genotypes were coded as 1. The SNPs associated with 
strength/endurance genotypes (Table S8) and the epigenetic modifiers (Table S10) were not 
included in this analysis. If either allele is marked as beneficial, then all of genotypes were 
scored 1. In the case of SNP rs1799945, the beneficial genotype is the heterozygous C/G, in this 
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D. Statistical Analysis  
 
1. Chi Squared Analysis  
 
For genotyping, a population is in Hardy-Weinberg Equilibrium (HWE) if the allele and genotype 
frequencies follow the following equation: 
Equation 2: Hardy-Weinberg Equilibrium Equation 
𝑝2 + 2𝑝𝑞 + 𝑞2 = 1 
 
Determining whether the population of participants in PHITE is in HWE was completed using 
the chi squared (χ2) statistic and the known minor allele frequencies for each of the SNPs. Chi 
squared is used to measure how expectations compare to actual observed data. For the 
expected results, the minor allele frequency (MAF) from dbSNP was used for each of the 182 
SNPs used. It is known that ethnicity can greatly impact genotype frequency; therefore, 
ethnicity was corrected for in the MAF. Figure 2 represents the ethnicity information of the 42 
completed participants. The gnomAD-Exomes MAF for Global was used for the White 
population (73.8% of PHITE subjects) and the gnomAD-Exomes Asian MAF was used for the 
Asian population (16.7%). Using the reported percentages of each in the 42 completers, the 
corrected MAF was calculated (Equation 3) for each SNP and used for the chi squared 
calculation. 
Equation 3: Equation for the Corrected Minor Allele Frequency Calculation (cMAF) 
 
𝐶𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 𝑀𝑖𝑛𝑜𝑟 𝐴𝑙𝑙𝑒𝑙𝑒 𝐹𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 (𝑐𝑀𝐴𝐹) = (𝑀𝐴𝐹 𝐺𝑙𝑜𝑏𝑎𝑙 ∗ 0.738) + (𝑀𝐴𝐹 𝐴𝑠𝑖𝑎𝑛 ∗ 0.167) 
 
 




Figure 2: Ethnicity Data for the First 42 Completers 
 
Pie chart showing the ethnicity data for the first 42 completers; purple-white (73.8%), 
blue-Asian (16.7%), red-Black or African American (7.1%), green-multiple races (2.4%) 
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2. K-Means Clustering and Performance Score 
 
K-means clustering is an unsupervised machine learning algorithm that groups individuals in a 
population together by similarities. This method was used according to (Yoo J, 2016) to group 
individuals in each of the 16 performance tests into 2 clusters: medium responders and high 
responders. Any performance change that is equal to 0 or less than 0 was classified into 
another cluster: non-responder. These clusters were also used to determine a performance 
score for each individual based on their cluster categorization for each physical performance 
test. This performance score was calculated by doing the following: each non-responder 
categorization was given a 0, medium responder was given a 1, and high responder was given a 
score of 2. All the scores for the 16 physical performance parameters were added up and make 
up the performance score.  
3. Fisher’s Exact Test  
 
The fisher’s exact test is a statistical analysis used to determine if there is a nonrandom 
association between two categorical variables. This test is similar to the chi squared analysis 
test but is more accurate when there is a small sample size. For the Fisher’s exact test in this 
study, two 2 by 2 contingency tables are used to compare the observed values of alleles in two 
sub groups and the calculated allele expected values for both groups (McDonald, 2014). The 
groups of SNP alleles compared in this study are between training groups A and B, and the K 
means clustered determined Non and High Responders groups for each of the physical training 
responses.  
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4. Analysis of Variance (ANOVA) 
 
To compare the physical performance tests with each of the SNPs genotypes, an analysis of 
variance (ANOVA) was performed. ANOVA is a statistical technique that is used to check if the 
means of two or more groups, in this case genotypes, are significantly different from one 
another. Each SNP genotype was plotted against the performance parameters and ANOVA was 
used to determine if any one genotype is associated with higher performance in the 16 training 
responses.  
5. Bonferroni Correction 
 
When testing multiple hypotheses at once, there is an increased probability of observing at 
least one significant result due to chance. In this case, the Bonferroni correction is used to 
decrease the chances of obtaining false-positive results when multiple tests are performed on a 
single data set (Goldman, 2008). The Bonferroni correction is simple: original p- value (0.05) 
divided by the number of tests performed (182 for the 182 SNPs in this study). This gives the 
new significance value of 0.0003 for any of the analyses in this study with multiple tests run.  
 
6. Genome Wide Association Study (GWAS) 
 
A common way to investigate the association of genetic variants to specific complex phenotype 
is a genome wide association study or GWAS. This is an observational study tool that can study 
hundreds or thousands of SNPs for the determination of alleles that correlate to different 
complex diseases or traits. This was done using the linear regression model that models 
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relationships between two variables by fitting a linear equation to the observed data. These 
determined associations are then plotted: each SNP is plotted against the negative log scale of 
the p-values. This kind of plot shows the association of each SNP clearly; the higher the point on 
the plot, the greater the association (lower the p-value) In this study, the 182 SNPs were 
compared to each of the 16 performance responses for association.  
III. RESULTS 
 
A. AIM I. Training Group A Versus B Physical Performance Parameters 
 
1. Group A Versus B: Individual Performance Parameters 
 
The first analysis completed was simply comparing each of the 16 physical performance 
parameters described in Table 2 against the blinded training groups A and B (a moderate 
intensity and high intensity). Significance in training response was determined by ANOVA. In 
this analysis, 15 of the 16 physical performance training responses did not significantly differ 
between training group A and B. Arm Lean Mass % Change was the only single physical 
parameter that had an overall higher response in training group A than training group B (shown 
in Figure 3).  
1. Group A Versus B: Performance Score  
 
Along with determining the differences for each individual physical performance parameter, a 
comparison of physical performance for each of the 42 completers was done. Determining 
overall performance was done by using the performance score determined by the performance 
clusters created using k-means clustering. Completers were separated by A or B training group 
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and the difference in performance score was found to be significantly different (Figure 4). Both 
results together show that even though the physical performance parameters individually did 
not significantly differ between the completers of training group A versus B (expect in the Arm 
Lean Mass % Change), in overall measure of performance, training group B completers were 
significantly more successful than the completers of training group A. Genetic variation in the 
completers of both groups also must be determined to see if the genetic contribution is 














Figure 3: Group A Versus Group B Comparison for Arm Lean Mass % Change  
Box and whisker plot separating group A versus group B for Arm Lean Mass % 
Change response. Indicated are the median, upper, and lower quartiles, minimum 
and maximum values, and outliers (which are values 1.5 times the difference 
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N = 22 N = 20 
 
















Figure 4: A Versus B Training Group Comparison for Performance Score  
Box and whisker plot separating group A versus group B for Performance Score. Indicated 
are the median, upper, and lower quartiles, minimum and maximum values, and outliers 
(which are values 1.5 times the difference between the upper and lower quartiles 
indicated as points; ** p value ˂ 0.01 
** 
                 Group A                                 Group B 
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B. AIM II. Investigate if genotype can be used to predict phenotype in 
individual training responses and in overall training response 
 
To investigate a usable genotype/allele predictor for the general population, the population of 
completers for PHITE had to be analyzed. To do this, chi squared analysis was completed to 
determine if any SNPs were out of equilibrium using an ethnicity-corrected minor allele 
frequency for comparison. Table 3 shows the results of this analysis and 14 SNPs had significant 
p values.  
Table 3: Chi Squared Analysis of all 42 Completers  
Gene(s) SNP ID Minor Allele Corrected MAF Chi squared p-value 
FAT2 rs10072841 C 0.38359468 6.21403 1.27E-02 
(intergenic) rs17231506 T 0.25437562 4.58778 3.22E-02 
(intergenic) rs1799768  - 0.247065 8.01014 4.70E-03 
CETP rs1800775 C 0.43784954 32.36959 0.00E+00 
LIPG rs2000813 T 0.2265238 4.92748 2.64E-02 
FTHFD  rs2002287 G 0.3373774 3.86362 4.93E-02 
ESR1 rs2234693 C 0.4144992 12.46752 4.00E-04 
NFKB1 rs28362491 * 0.3862216 4.91928 2.66E-02 
EPAS1 rs4035887 A 0.3199796 6.71720 9.50E-03 
TYMS rs502396 T 0.3848382 7.46675 6.30E-03 
(intergenic) rs5082 G 0.2567174 8.20291 4.20E-03 
(intergenic) rs699947 A 0.32672976 5.29288 2.14E-02 
GNAS rs7121 C 0.40546854 5.27060 2.17E-02 
TCERG1l rs7893895 C 0.4336136 5.32885 2.10E-02 
 
This means that those SNPs genotypes are out of equilibrium according to our corrected minor 
allele frequency and could lead to false positives of significance in the later analyses. It is for 
this reason any of the SNPs in Table 3 will not be considered if significant in any of the five-
following predictor analyses described. 
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1. Beneficial Allele Score 
 
The first analysis performed was to determine if the beneficial allele score calculated for each 
completer could be used to determine the k-means clustering group (High, Medium or Non-
Response) for individual performance of each of the 16 tests in Table 2. To do this, each of the 
performance response k-means clustering groups were plotted against the beneficial allele 
score. Figure 5 shows the beneficial allele score versus the clusters for the vertical jump 
categorization. The means of each cluster for beneficial allele score increase with the correct 
clusters (the highest median is the high response group) but this change was not determined to 
be significant (p=0.2405) using ANOVA. In the other 15 training responses, similar trends were 
seen but none were statistically significant. This shows that, with the current completers in 
consideration, the beneficial allele score is not able to correctly determine the k-means 

















Figure 5: Beneficial Allele Score versus Vertical Jump Categorization 
Box and whisker plot of beneficial allele score versus the k- means clustering categorizations for 
vertical jump. Indicated are the median, upper, and lower quartiles, minimum and maximum 
values, and outliers (which are values 1.5 times the difference between the upper and lower 
quartiles indicated as points. The means increase with the clusters; the highest median for 
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2. Performance Score  
 
Using the performance score calculated using the k-means clustering groups (Non, Medium, 
and High-Responders) the next strategy was to determine whether any individual SNP genotype 
could predict overall performance. This was done by plotting the performance score against 
each of the 182 SNP genotypes and using ANOVA to determine significance. This analysis 
resulted in 6 SNPs that had a specific genotype associated with higher/lower performance score 
and are shown in Table 4.  
Table 4: SNPs Shown to be Associated with Performance Score 
SNP ID Gene P value 
rs11096663 PUM2 | RHOB 0.0316 
rs1546570 DIS3L 0.0063 
rs1801394 MTRR 0.0162 
rs2276731 FTHFD  0.0360 
rs328 LPL 0.0182 
rs7964046 PDE3A 0.0302 
 
The Bonferroni correction was applied to the ANOVA analysis, which resulted in having no SNPs 
significantly associated with performance score. For further investigation, the p value of 0.05 
will be used for the performance score and the 6 SNPs in Table 4 will be further characterized. 
Each of the six SNPs were investigated further and plotted for determination of the beneficial 
allele associated with the performance score.  
The first SNP is rs11096663, an A/G SNP in the intergenic region between gene PUM2 (Pumilio 
homolog 2) and RHOB (Ras Homolog B) in chromosome 2. In the literature this SNP has been 
shown to be a predictor of high response in VO2max (Yoo J, 2016). Figure 6 shows the 
genotypes for rs11096663 plotted against the performance score. The box and whisker plot 
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show that the G/G genotype is associated with higher overall performance and is significantly 
different from the A/G and A/A genotypes. 
Without considering the outliers in the A/A genotype, the median is higher than the 
heterozygote, but the A/A genotype did also contain the lowest performance score outliers 
compared to either of the other genotypes. 
SNP rs1546570 is an A/C intron variant in the DIS3L (DIS3 like exonuclease 1). In the literature, 
this SNP has been shown to be a predictor of high response in VO2max (Timmons, 2009). Figure 
7 shows the genotypes for rs1546570 plotted against the performance score. The more 
beneficial genotype is A/C with the highest median, and the C allele is more beneficial than the 
A allele significantly with a p=0.0063. This association could be skewed due to only three A/A 
























Figure 6: SNP rs11096663 genotypes versus the Performance Score  
Box and whisker plot of Performance Score versus rs11096663 a SNP in the intergenic 
region between genes PUM2 and RHOB. Indicated are the median, upper, and lower 
quartiles, minimum and maximum values, and outliers (which are values 1.5 times the 




































Figure 7: SNP rs1546570 genotypes versus the Performance Score  
Box and whisker plot of Performance Score versus rs1546570. Indicated are the median, 
upper, and lower quartiles and minimum and maximum values ; *p value ˂ 0.05 and  
** p value ˂ 0.01 
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The SNP rs1801394 is an A/G missense variant in the MTRR (5-methyltetrahydrofolate-
homocysteine methyltransferase reductase). When the A allele is present, isoleucine at position 
22 and when the G allele is present, there is a switch from isoleucine to methionine. The 
change to methionine doesn’t create a non-functional protein, but it does have a lower affinity 
for its target and affects the body’s homocysteine levels (Olteanu H, 2002). In the literature, 
this SNP has been shown to be a predictor of lower BMI and decrease chance of obesity (Bokor 
S, 2011). Figure 8 shows the genotypes for rs1801394 plotted against the performance score. In 
the first 42 completers, the A/G genotype and the A allele are shown to be more beneficial to 
overall performance. The outliers also confirm this conclusion since the lower performance 
scores fall into the G allele genotypes. 
Another SNP identified to associated with overall performance is rs2276731. This SNP is a C/T 
intron variant in the FTHFD (aldehyde dehydrogenase 1 family member L1) gene. This gene 
encodes a protein involved in one carbon metabolism and is an epigenetic modifier that plays a 
vital role in DNA methylation (Min-Ae Song, 2016). This SNP has never been shown to be a 











Figure 8: SNP rs1801394 genotypes versus the Performance Score  
Box and whisker plot of Performance Score versus rs1801394. Indicated are the 
median, upper, and lower quartiles, minimum and maximum values, and outliers 
(which are values 1.5 times the difference between the upper and lower quartiles 
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Figure 9 shows the genotypes for rs2276731 plotted against the performance score. In this 
case, the C/C genotype seems to be the beneficial for overall performance, but in the first 42 
completers there was only one with the genotype C/C for this SNP. This makes it difficult to 
determine if the C/C genotype is associated with higher performance or if this is a false positive 
association. The addition of more completers could be very beneficial in determining the extent 
of this novel SNP association with overall physical training response. The SNP rs328 is a C/G 
stop gained variant in the LPL (lipoprotein lipase) gene. The C allele sequence creates a full-
length protein, whereas the G allele creates a premature stop codon, leading to a shortened 
transcript. This short variant creates low activity LPL that can lead to and increased chance in 
insulin resistance. In the literature, this SNP has been shown to be a predictor of increased BMI 



















Figure 9: SNP rs2276731 genotypes versus the Performance Score  
Box and whisker plot of Performance Score versus rs2276731 Indicated are the 
median, upper, and lower quartiles, minimum and maximum values, and outliers 
(which are values 1.5 times the difference between the upper and lower quartiles 
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Figure 10 shows the genotypes for rs328 plotted against performance score. This shows that 
the beneficial allele is most likely the G allele due to the increase in performance score seen 
between the C/C and the C/G box plots. Without any completers that have the G/G genotype, it 
is hard to confirm this association, so increasing the sample size for genotyping would be 
beneficial.  
The last SNP that was shown to be a predictor of overall performance is rs7964046. This SNP is 
a C/T intron variant in PDE3A (phosphodiesterase 3A) gene. In the literature, this SNP has been 
shown to be a predictor of a lower heart rate during exercise (Rankinen T S. Y., 2012). Figure 11 
shows the genotypes for rs7964046 plotted against performance score. This figure shows that 
the T/T genotype is clearly beneficial for overall performance response compared to the other 
genotypes. In conclusion, all six SNPs determined by the performance score to be significantly 
associated with overall performance have specific genotypes that could be used as part of a 
model for predicting training response.  
The performance score was also plotted against the beneficial allele score to determine if 
beneficial allele increases with the overall performance. This was done by doing a linear 
regression between the beneficial allele score and performance score (Figure 12). It was not 
found to be a significant association, with the R value = 0.027, but is trending in the right 





















Figure 10: SNP rs328 genotypes versus the Performance Score  
Box and whisker plot of Performance Score versus rs328. Indicated are the 
median, upper, and lower quartiles, minimum and maximum values, and outliers 
(which are values 1.5 times the difference between the upper and lower quartiles 































Figure 11: SNP rs7964046 genotypes versus the Performance Score  
Box and whisker plot of Performance Score versus rs7964046. Indicated are the median, 
upper, and lower quartiles, minimum and maximum values, and outliers (which are 
values 1.5 times the difference between the upper and lower quartiles indicated as 
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Figure 12: Beneficial Allele Score Versus Performance Score 
A linear regression plot of beneficial allele score versus performance score with a best of 
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3. Fisher’s Exact Test 
 
The fisher’s exact test was completed to compare the number of alleles for each of the SNPs 
between two categorical variables. This was completed between groups A and B and between 
the k-means clustered categories High Responders and Non-Responders. The was completed by 
comparing the observed number of alleles in each category and comparing them to calculated 
expected alleles. This analysis determined 83 SNPs that were significantly different than what 
was expected in either of the two categories with a p-value of less than 0.05. When this data 
set used the Bonferroni correction, three SNPs were still significant: rs11622895 (EPAS1), 
rs1801394 (MTRR), and rs2979481 (RBPMS). These SNPs were plotted against the Performance 
categories they were found to be associated with to determine which allele was associated with 
which k-means clustered group (high or non-responders). Figures 13-15 show these results and 
Table 5 summarizes the associations.  
 
Table 5: Bonferroni Corrected Fisher’s Exact Test SNP Results 
SNP ID Gene Performance Results P value 
rs11622895 EPAS1 Knee Peak Power T (High Response) 0.0002 
rs1801394 MTRR Lat Pull A (High Response) 0.0003 
rs2979481 RBPMS Knee Ext C (High Response) 0.0003 
 
This analysis results in 3 SNPs that have alleles associated with high performance for specific 
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Figure 13: Non-Responders Versus High-Responders for rs11689011 – EPAS1 for Knee Peak 
Power % Change 
Response group allele distributions for SNPs identified as significant by Fisher’s exact test, 
 p value ˂0.0003 
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Figure 14: Non-Responders Versus High-Responders for rs1801394 – MTRR for Lat Pull % 
Change 
Response group allele distributions for SNPs identified as significant by Fisher’s exact test, 
 p value ˂0.0003 
 
 
















Knee Extension % Change 
rs2979481 – RBPMS 
High-Responders 
Knee Extension % Change 
rs2979481 – RBPMS 
Figure 15: Non-Responders Versus High-Responders for rs2979481 – RBPMS for Knee 
Extension% Change 
Response group allele distributions for SNPs identified as significant by Fisher’s exact test, 
 p value ˂0.0003 
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4. ANOVA Analysis  
 
ANOVA analysis is an easy way of comparing categorical data to continuous data. This was done to 
determine whether an individual SNP genotype could be used as a predictor of each of the 16 training 
responses. In this case, each of the SNP genotypes (182 SNPs) were plotted against each of the training 
responses (16 different tests). This analysis lead to 183 times a SNP was predictive of one of the training 
responses (see supplemental tables S11-S26 for all the SNPs, the associated training response, and the 
p-value determined by the ANOVA). Due to the large number of tests run on a single data set, the 
Bonferroni correction was used to attempt to avoid any false positive associations. Using the new 
significant p-value of 0.0003, there were only 5 times a SNP was predictive of one of the training 
responses and these are described in Table 6.  
Table 6: SNPs Shown to Predict Specific Training Responses by ANOVA 
SNP ID Gene Performance P value 
rs10248479 TFEC AP, RP 0.0002, 0.0002 
rs1532723 ANO4 Squat 0.0001 
rs4994 ADRB3 Vertical Jump 0.0001 
rs7386139 DEPDC6 Chest Press 0.0002 
 
Figures 16-20 show the genotypes plotted for the 5 SNPs associated with higher performance in 
one of the training responses by ANOVA analysis. In conclusion, these four SNPs determined by 
the ANOVA analysis to be significantly associated with specific training responses could be used 

















Figure 16: SNP rs10248479 Association with Anaerobic Peak Power % Chg 0-12 By ANOVA  
Box and whisker plot of AP versus rs10248479 genotypes. Indicated are the median, 
upper, and lower quartiles and minimum and maximum values and the number of people 
in each group as indicated above the box and whisker plots; *p value ˂ 0.05 
































































Figure 17: SNP rs10248479 Association with Relative Peak Power % Chg 0-12 By ANOVA  
Box and whisker plot of RP versus rs10248479 genotypes. Indicated are the median, 
upper, and lower quartiles and minimum and maximum values and the number of 
people in each group as indicated above the box and whisker plots;  








































Figure 18: SNP rs1532723 Association with Squat % Chg 0-12 By ANOVA 
Box and whisker plot of RP versus rs1532723 genotypes. Indicated are the median, 
upper, and lower quartiles and minimum and maximum values and the number of people 
in each group as indicated above the box and whisker plots; *p value ˂ 0.05  
 
 









































Figure 19: SNP rs4994 Association with Vertical Jump % Chg 0-12 By ANOVA 
Box and whisker plot of RP versus rs4994 genotypes. Indicated are the 
median, upper, and lower quartiles and minimum and maximum values and 
the number of people in each group as indicated above the box and whisker 
plots; **p value ˂ 0.01  
 
 


































Figure 20: SNP rs7386139 Association with Chest Press % Chg 0-12 By ANOVA 
Box and whisker plot of RP versus rs7386139 genotypes. Indicated are the 
median, upper, and lower quartiles and minimum and maximum values and the 
number of people in each group as indicated above the box and whisker plots; 
**p value ˂ 0.01  
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5. GWAS Analysis  
 
An alternate technique to the ANOVA analysis is an observational test called the GWAS. This test was 
also used to determine if an individual SNP could be used in a predictor to one of the 16 training 
responses. The Bonferroni correction was also used for this test, so the p-value for association was 
0.0003. Figure 21 shows the Manhattan plots for the training responses that have SNPs with significant 
associations seen above the solid red lines on the plots. Table 7 summarizes the SNPs found with 
significant associations and the training responses that associated with each.  
Table 7: SNPs Shown to Predict Specific Training Responses by GWAS 
SNP ID Gene Performance P Value 
rs1044498 ENPP1 Squat 0.0003 
rs1800562 (intergenic) Lat Pull 0.00025 
rs1950902 MTHFD1 Arm LM 0.00028 
rs2228059 IL15RA Lat Pull 0.00026 
rs3025684 CREBBP Squat 0.00027 
rs3770991 NRP2 Arm LM 0.00025 
rs8192678 PPARGC1A AP, RP 0.00001, 0.00001 
rs9340799 ESR1 Arm LM 0.00025 
 
In conclusion, all eight SNPs determined by the GWAS analysis to be significantly associated 
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Figure 21: GWAS Plots for the Training Responses that had Significant SNP Associations 
GWAS Manhattan Plots, where the orange line represents the Bonferroni corrected p value = 2.75x10-4;  
significant associations are labeled with dbSNP ID. 
 




Understanding the role that genetics play in physical training response is an important topic in 
military research. Investigating this connection and using it to create models of training 
response could save the military millions of dollars by determining risk of injury or inadequate 
physical fitness leading to dropouts. To investigate the genetic contribution to training 
response, genotyping of several SNPs previously identified to be associated with different parts 
of individual physical training response was completed for 42 individuals. These SNPs were 
chosen to cover a wide range of physical performance responses including aerobic capacity, 
endurance/strength, muscle volume, etc. (Table 2). Some SNPs that were chosen were also 
indicative of traits that would contribute negatively to physical performance such as increased 
BMI or lower bone density. These SNP genotypes were compared to the physical training 
responses that were measured for each of the 42 completers of the blinded training groups 
(high versus moderate intensity) and are described in Figure 1. Connecting the SNP genotypes 
to the physical training responses was used to investigate the differences in training groups and 
whether genotype can be used to determine phenotype (training response).  
Due to the training group being blinded, it is not known which protocol each of the participants 
completed. It is for this reason that it was of great interest to investigate the performance 
response in each of the training groups: Group A versus Group B. This was first done by 
separating each of the 16 training responses by A and B and comparing the two. ANOVA was 
used to determine that there was no significant difference between the two, except in the case 
of the Arm Lean Mass Change (Figure 3). This shows that on an individual performance level, 
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the participants virtually responded the same no matter what training group was completed. 
Next, overall performance was considered by using k-means clustering groups (non, medium, 
and high responders) for each of the 16 training responses to score overall physical 
performance (performance score). When the performance score was separated by group A and 
B, there was a significant difference between the two groups (p=0.02). Group B had a much 
higher overall performance score than group A (Figure 4). This shows that even though 
individual phenotype responses were similar for completers in both groups, the overall 
performance of the participants was much greater if they completed training group B than 
group A. Due to the greater capacity to see larger increases in training response in males 
compared to females, the gender composition for each group was investigated. It was found 
that the gender make-up of each group wasn’t significantly different with group A having 13 
females and 9 males and group B having 15 females and 5 males. This shows that the difference 
in training response is not driven by a gender disequilibrium between the two groups. In 
conclusion, individual training responses did not differ between the two training groups 
significantly, but the overall performance of the completers was significantly different between 
the two groups, with group B having the higher performance.  
Determining whether genotyping can be used as a predictor for training response was the next 
aim of this project. Using the 182 determined physical performance SNP genotypes, it was 
hypothesized that this could be used as a model of prediction for training response. To 
investigate this hypothesis, five different analyses were used to investigate whether genotype 
could be used as a predictor for training response: ANOVA of beneficial allele score, ANOVA of 
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performance score, Fisher’s exact test, ANOVA of individual performance results, and GWAS 
analysis 
The beneficial allele score was determined using the literature-defined beneficial alleles. This 
beneficial allele score was calculated for each of the 42 completers and compared to the 
training response k-means categories by ANOVA. This was done to determine whether the 
beneficial allele score could predict whether a completer would fall into the k-means clustered 
determined non, medium, or high-responder performance categories for each of the training 
responses. It was found that the beneficial allele score could not significantly predict the 
performance response. Even though it was not found to be significant, the beneficial allele 
score did seem to trend in the right direction, with the higher beneficial allele scores falling into 
the high-responders. A future direction for this study would be to perform predication 
statistics, this would allow for a determination of accuracy of how many times the beneficial 
allele score can correctly determine high performance. This study currently has a rather small 
sample size and with more completers, this trend might become clearer and could be 
statistically significant. This result could also be re-evaluated by investigating the each of the 
SNPs beneficial allele determination. Some of the literature determined beneficial alleles were 
difficult to classify and might be conflicting with the data gathered from this study. Another 
approach that can be taken in this case would be to determine the beneficial alleles according 
to the data gathered in this study and then use that corrected beneficial allele score moving 
forward with more completers. This could be a more accurate beneficial allele score that might 
be able to be used as a model for training response. Another future direction for the beneficial 
allele score could be to separate the SNPs into their respective physical fitness categories and 
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use separate beneficial allele scores for specific physical training responses. For example, take 
only the SNPs for aerobic capacity/endurance and calculate a beneficial allele score using those 
SNPs. This would then be used to compare against VO2peak categories (non, medium, and high 
response) by seeing if it can predict which category a person would fall into. This could be done 
with multiple physical training responses and might be a better way to use the beneficial allele 
score as a predictor.  
Another tactic used toward determining a model for training response was using the 
performance score. This was done by plotting the performance score by every individual SNP 
genotype. The associations were analyzed using ANOVA and any significantly associated 
genotypes were analyzed for positive or negative correlation. Using a p-value of 0.05, this 
analysis found 6 SNPs that had a specific genotype associated with performance score. In this 
analysis, it is acknowledged that if the Bonferroni correction was applied to this set of 
associations, then there were no significant SNPs associated with overall performance for the 
first 42 completers. For the 6 SNPs found, each SNP was analyzed, and the beneficial genotypes 
were determined due to the results of this study and compared to the literature determined 
beneficial alleles (Table 8).   
Table 8: SNPs Beneficial Alleles Associated with Overall Performance  
SNP ID Gene Beneficial Allele Literature Beneficial Allele  
rs11096663 PUM2 | RHOB G A 
rs1546570 DIS3L C A 
rs1801394 MTRR A G 
rs2276731 FTHFD  C n/a 
rs328 LPL G C 
rs7964046 PDE3A T T 
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As seen in Figures 6-11 show each of the SNPs genotypes compared to the performance score. It is 
recognized that there is a large variation is performance score for each of the genotypes which causes a 
lot of overlap between the quartiles of the box and whisker plots. This separation could improve with 
more completers and make a clearer association. In Table 8, the beneficial alleles determined in our 
study do not match up with the beneficial alleles determined in the literature review. This could 
be due to the amount of information about these SNPs found in the current literature. Many of 
these SNPs were shown to be associated with physical fitness/training response but were not 
specific in the allele that was associated. If information was not provided in the literature for 
which allele was specifically associated, the minor allele was chosen. This might explain some of 
the discrepancies between this study’s determined beneficial alleles and the literature 
determined. A future direction for this part of the study could be to create a new beneficial 
allele categorization based on the first 42 completers training responses and use to this new 
classification against the rest of the completers in this study. This also could be used to 
investigate the beneficial allele score’s ability to predict which k-means clustering group each 
completer would fall into.  
The performance score was also plotted against the beneficial allele score to determine with 
the beneficial allele score could predict overall performance (Figure 12). This linear regression 
best fit line had an R2 value of 0.027. The R2 value explains the amount of variance the line 
shows compared to the total variance. In a perfect correlation, the R2 value would be 1, so the 
closer the value is to 1 the better the line of best fit. In this case, the R2 value is very low which 
means the beneficial allele score does not clearly predict the overall performance in this study.  
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The trouble with the determined SNP associations for performance score is the small sample 
size in this study. This lead to a few SNPs’ minor alleles only having a couple completers, which 
could result in false positive or false negative associations. More completers would greatly 
increase the confidence of the 6 SNPs determined to be associated with overall performance 
score. In summary, the SNPs in Table 8 are associated with overall performance significantly 
(p=0.05) and could be used in a predictor to overall training response performance, but 
additional subjects are needed to decrease the chance that these are false positive 
associations.  
The fisher’s exact test model was used to investigate whether specific alleles for the 182 SNPs 
were associated with high or non-response in the 16 different training responses, group A 
versus group B, or overall performance scores high versus non-responders. This statistical 
analysis determined several SNPs that had alleles associated with several different training 
responses (Table 5). These alleles could potentially be used in a predictor for physical training 
response. The three SNP associations determined with the Bonferroni corrected p value 
(0.0003) were just at the significance cutoff. An increase in the number of completers could 
increase the strength of some of the associations seen. The SNP rs2979481 association with 
high response for Knee Extension % Change 0-12 weeks had only 5 completers in the non-
response category, which could make the C allele association be a false positive for the high 
response category. An increase in the number of completers could increase the strength of 
some of the associations seen and create new associations with some of the other 83 SNPs that 
had significance above the Bonferroni correction.  
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ANOVA analysis was another approach taken to determine a model for physical training 
response. This test was used to determine whether an individual SNP could predict an 
individual training response. This analysis determined 183 times a single SNP was predictive of a 
single training response. With a large number of tests being performed on the same data set, 
the Bonferroni correction was used to determine a more specific set of associations. The 
correction narrowed down the list to 5 matches (Table 6). Figures 16-20 show the genotypes for 
the 5 associated SNPs plotted against the appropriate training response. Several of SNPs only 
had one or two completers for the minor homozygote which could lead to false positive 
associations. For example, rs10248479 the G/G genotype showed a very high performance for 
AP and RP, but there was only one completer that had this genotype. Due to this, the G/G 
genotype in this study is associated with high performance for AP and RP but with more 
completers, this association might be disproved. Further completers will give a clearer picture 
of the significant associations with the ANOVA analysis.  
These SNPs could be used as part of a prediction model of specific training responses. An 
alternative test, called a GWAS, was also performed to determine association for each allele. 
This test also used the Bonferroni correction to narrow down the significant associations to the 
strongest correlations (Table 7). This analysis also found significant associations between SNPs 
and specific training responses. These similar techniques were able to determine possible 
predictors of training response (genotypes and alleles) but each list of SNPs is unique. This 
difference is most likely due to the difference in calculations of significance between the two 
different analyses. The ANOVA uses multiple t-tests to determine if each genotype significantly 
differs from the other genotypes. The GWAS uses the SNP allele frequencies of two or more 
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separated groups (in this case the training response groups) to determine significance. This 
variation in calculation leads to different results in associations. Both the ANOVA and the GWAS 
analyses determined SNPs are good candidates for looking at individual training response 
predictors.  
In summary, this study determined that the completers of the two different training protocols 
do not respond significantly different on individual phenotype responses, but overall 
performance is significantly greater in training group B compared to group A.  Using multiple 
analysis, SNP performance associations were determined for individual training responses, such 
as chest press or lat pull, and for overall performance taking into consideration all the training 
responses; these are summarized in Table 9. All these SNPs are candidates for a genotypic 
model of training response and could be used to predict an individual’s success in a physically 
demanding situation, such as basic training, before the situation is started.  
Table 9: Summary Table for all SNPs Found to be Possible Training Response Predictors 
SNP ID Gene Performance Analysis P value 





rs1546570 DIS3L Overall Performance Performance Score 0.0063 
rs1801394 MTRR Overall Performance 
Lat Pull 
Performance Score 
Fisher’s Exact Test 
0.0162 
0.0003 
rs2276731 FTHFD  Overall Performance Performance Score 0.0360 
rs328 LPL Overall Performance Performance Score 0.0182 
rs7964046 PDE3A Overall Performance Performance Score 0.0302 
rs11622895 EPAS1 Knee Peak Power Fisher’s Exact Test 0.0002 
rs2979481 RBPMS Knee Ext Fisher’s Exact Test 0.0003 
rs10248479 TFEC AP, RP ANOVA 0.0002, 0.0002 
rs1532723 ANO4 Squat ANOVA 0.0001 
rs4994 ADRB3 Vertical Jump ANOVA 0.0001 
rs7386139 DEPDC6 Chest Press ANOVA 0.0002 
rs1044498 ENPP1 Squat GWAS 0.0003 
rs1800562 (intergenic) Lat Pull GWAS 0.00025 
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SNP ID Gene Performance Analysis P value 
rs1950902 MTHFD1 Arm LM GWAS 0.00028 
rs2228059 IL15RA Lat Pull GWAS 0.00026 
rs3025684 CREBBP Squat GWAS 0.00027 
rs3770991 NRP2 Arm LM GWAS 0.00025 
rs8192678 PPARGC1A AP, RP GWAS 0.00001, 0.00001 
rs9340799 ESR1 Arm LM GWAS 0.00025 
 
Another aim of this project was to determine if genotype could predict whether an individual 
would perform better in different training groups: moderate intensity versus high intensity. Due 
to the number of completers being small, this could not be investigated further at this time. 
When the current data were split into the training groups for genotypes, the power was not 
sufficient to determine true differences in each genotype for each SNP (data not shown). It was 
also determined that due to lower minor allele frequencies, when the data were split into 
group A versus group B, sometimes the minor alleles only showed up in one group or the other 
due to few completers having this genotype. This lead possible to false positives for minor 
alleles being associated with only one group or the other. This could be a possible future 
direction of this part of the study that could lead to model predictors of what type of training 
would be best for different individuals.  
Overall this study shows the importance of considering genotype in any model of physical 
performance and moving forward should be considered in the PHITE project. In the end, the 
overall aim would be to incorporate the genotyping date and the epigenetic data together into 
a single model for physical training response.  
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V. FUTURE DIRECTIONS 
 
The project PHITE is set to continue until the total completers is 150 people. Currently, there 
are only plans to continue the epigenetic side of the project. The genotyping using the blood 
samples drawn at time zero will only be done until the current supply of materials is used. The 
data presented in this thesis supports the importance in considering genotype in any model of 
physical training response. The candidate phenotype predictors found in AIM II of this project 
are important to pursue further and could be used as part of an overall physical training 
response model in the future. In general, the overall final aim of PHITE is to determine a 
physical training response model for different types of training. It is believed that the best way 
to complete this is by incorporate the genotyping data and the epigenetic data together into a 
single model of physical training response.  
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VI. SUPPLEMENTARY DATA 
 
Supplementary Tables S1 through S3 contain the raw data for the first 42 completers. The 
genotypes are colored coded using the following:       Major Homozygote,       Heterozygous, and  
     Minor Homozygote. 
Table S1: Raw Genotyping Data for the First 16 Completers 
Group A A B B A A B B A A A B B B B A 
Gene(s) SNP ID 1 4 6 8 15 17 20 21 23 25 31 34 38 39 41 42 
FAT2 rs10072841                 
MATN2 rs10099863                 
PDK4 rs10247649                 
TFEC rs10248479                 
ADRB2 rs1042713                 
ADRB2 rs1042714                 
ENPP1 rs1044498                 
TTN rs10497520                 
PPP1CC rs1050587                 
PPARD rs1053049                 
CYP2D6 rs1065852                 
PLA2G2A rs10732279                 
HBB rs10768683                 
(intergenic) rs10861553                 
AMN1 rs11051548                 
(intergenic) rs1107946                 
(intergenic) rs11096663                 
LEPR rs1137101                 
NME7 rs1138486                 
HIF1A rs11549465                 
ID3 rs11574                 
RNASE1 rs11622895                 
EPAS1 rs11689011                 
(intergenic) rs11770725                 
(intergenic) rs12079745                 
DIO1 rs12095080                 
(intergenic) rs12535708                 
(intergenic) rs12535747                 
GABPB1 rs12594956                 
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KCNH7 rs12613181                 
TMEM195 rs12672644                 
YWHAQ rs12692388                 
API5 rs12789205                 
CREBBP rs130021                 
LOC100288831 rs13060995                 
HDAC2 rs13212283                 
LEP rs13245201                 
(intergenic) rs1341439                 
(intergenic) rs1349419                 
STS rs13648                 
LOC730100 rs1451462                 
ANO4 rs1532723                 
DIS3L rs1546570                 
GPRIN3 rs1560488                 
(intergenic) rs1570360                 
NPY rs16139                 
EPS1 rs17039192                 
LOC100129278 rs17044554                 
(intergenic) rs17231506                 
TTC17 rs17508783                 
AMPD1 rs17602729                 
(intergenic) rs17782313                 
(intergenic) rs1799768                 
FABP2 rs1799883                 
HFE rs1799945                 
COL1A1 rs1800012                 
CNTF rs1800169                 
PPARA rs1800234                 
TGFB1 rs1800470                 
HFE rs1800562                 
(intergenic) rs1800588                 
(intergenic) rs1800629                 
CETP rs1800775                 
LOC541472 rs1800795                 
UCP3 rs1800849                 
MTHFR rs1801131                 
MTHFR rs1801133                 
ADRB1 rs1801252                 
ADRB1 rs1801253                 
MTRR rs1801394                 
MYOSTAIN rs1805086                 
MTR rs1805087                 
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ACTN3 rs1815739                 
SPATA17 rs1832544                 
EPAS1 rs1867785                 
PTPRT rs1885831                 
MTHFD1 rs1950902                 
LIPG rs2000813                 
FTHFD rs2002287                 
VEGFA rs2010963                 
PPARD rs2016520                 
p300 (EP300) rs20551                 
GCH1 rs2057368                 
NOS3 rs2070744                 
RAB6A rs2140892                 
IL15RA rs2228059                 
VDR rs2228570                 
ESR1 rs2234693                 
H19 rs2251375                 
REEP3 rs2252578                 
CREB1 rs2253206                 
DOCK2 rs2270895                 
FTHFD rs2276731                 
TFAM rs2306604                 
LRP5 rs2306862                 
HYDIN rs235987                 
CREB1 rs2360969                 
NRF1 rs2402970                 
SLC22A3 rs2457571                 
(intergenic) rs2542729                 
BTAF1 rs2792022                 
NFKB1 rs28362491                 
MYLK rs28497577                 
ACVR1B rs2854464                 
(intergenic) rs2854744                 
RBPMS rs2979481                 
CREBBP rs3025684                 
TOM1L2 rs3183702                 
LPL rs320                 
CHRM2 rs324640                 
LPL rs328                 
RYR2 rs34967813                 
NUAK1 rs3741886                 
ATP1B1 rs3766031                 
ATP1B1 rs3766044                 
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NRP2 rs3770991                 
PDK4 rs3779478                 
GRHL1 rs3791749                 
EPAS1 rs4035887                 
TUSC1 rs4246861                 
PPARA rs4253778                 
CPVL rs4257918                 
APOE rs429358                 
PHF2 rs4498613                 
(intergenic) rs4522375                 
COMT rs4680                 
PIWIL1 rs4759659                 
ADD1 rs4961                 
LRP5 rs4988300                 
ADRB3 rs4994                 
TYMS rs502396                 
AGT rs5050                 
(intergenic) rs5082                 
EDN1 rs5370                 
GNB3 rs5443                 
NTRK2 rs615189                 
LRP5 rs634008                 
YWHAQ rs6432018                 
RTP1 rs6444210                 
SVIL rs6481619                 
GABARAPL2 rs6564267                 
UST rs6570913                 
(intergenic) rs659366                 
UCP2 rs660339                 
PON1 rs662                 
APOA1-AS rs670                 
p300  rs67744457                 
MIR538 rs6865159                 
NRF1 rs6949152                 
AGT rs699                 
(intergenic) rs699947                 
CETP rs708272                 
GNAS rs7121                 
IGF1 rs7136446                 
TMX1 | 
FRMD6 rs7154161                 
GABPB1 rs7181866                 
CYP19A1 rs727479                 
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MIPEP rs7324557                 
DEPDC6 rs7386139                 
APOE rs7412                 
C7orf74 rs7792872                 
TCERG1l rs7893895                 
NHLRC2 rs7901769                 
PDE3A rs7964046                 
GABPB1 rs8031031                 
LOC100131241 rs8069419                 
CKMM rs8111989                 
PRLHR rs8192524                 
PPARGC1A rs8192678                 
DRG2 rs854762                 
DRG2 rs854813                 
OR6N2 rs857838                 
ALX4 rs903514                 
MYLIP rs909562                 
ESR1 rs9340799                 
FOXQ1 rs9378283                 
SLFN11 rs938298                 
HDAC2 rs9488289                 
RTP1 rs9869355                 
RTP1 rs9872701                 
FTO rs9930506                 
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Table S2: Raw Genotyping Data for the Completers 17-29 
Group A B A B B A B B A A B A B 
Gene(s) SNP ID 43 44 45 47 48 49 50 51 54 56 58 62 63 
FAT2 rs10072841              
MATN2 rs10099863              
PDK4 rs10247649              
TFEC rs10248479              
ADRB2 rs1042713              
ADRB2 rs1042714              
ENPP1 rs1044498              
TTN rs10497520              
PPP1CC rs1050587              
PPARD rs1053049              
CYP2D6 rs1065852              
PLA2G2A rs10732279              
HBB rs10768683              
(intergenic) rs10861553              
AMN1 rs11051548              
(intergenic) rs1107946              
(intergenic) rs11096663              
LEPR rs1137101              
NME7 rs1138486              
HIF1A rs11549465              
ID3 rs11574              
RNASE1 rs11622895              
EPAS1 rs11689011              
(intergenic) rs11770725              
(intergenic) rs12079745              
DIO1 rs12095080              
(intergenic) rs12535708              
(intergenic) rs12535747              
GABPB1 rs12594956              
KCNH7 rs12613181              
TMEM195 rs12672644              
YWHAQ rs12692388              
API5 rs12789205              
CREBBP rs130021              
LOC100288831 rs13060995              
HDAC2 rs13212283              
LEP rs13245201              
(intergenic) rs1341439              
(intergenic) rs1349419              
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STS rs13648              
LOC730100 rs1451462              
ANO4 rs1532723              
DIS3L rs1546570              
GPRIN3 rs1560488              
(intergenic) rs1570360              
NPY rs16139              
EPS1 rs17039192              
LOC100129278 rs17044554              
(intergenic) rs17231506              
TTC17 rs17508783              
AMPD1 rs17602729              
(intergenic) rs17782313              
(intergenic) rs1799768              
FABP2 rs1799883              
HFE rs1799945              
COL1A1 rs1800012              
CNTF rs1800169              
PPARA rs1800234              
TGFB1 rs1800470              
HFE rs1800562              
(intergenic) rs1800588              
(intergenic) rs1800629              
CETP rs1800775              
LOC541472 rs1800795              
UCP3 rs1800849              
MTHFR rs1801131              
MTHFR rs1801133              
ADRB1 rs1801252              
ADRB1 rs1801253              
MTRR rs1801394              
MYOSTAIN rs1805086              
MTR rs1805087              
ACTN3 rs1815739              
SPATA17 rs1832544              
EPAS1 rs1867785              
PTPRT rs1885831              
MTHFD1 rs1950902              
LIPG rs2000813              
FTHFD rs2002287              
VEGFA rs2010963              
PPARD rs2016520              
p300 (EP300) rs20551              
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GCH1 rs2057368              
NOS3 rs2070744              
RAB6A rs2140892              
IL15RA rs2228059              
VDR rs2228570              
ESR1 rs2234693              
H19 rs2251375              
REEP3 rs2252578              
CREB1 rs2253206              
DOCK2 rs2270895              
FTHFD rs2276731              
TFAM rs2306604              
LRP5 rs2306862              
HYDIN rs235987              
CREB1 rs2360969              
NRF1 rs2402970              
SLC22A3 rs2457571              
CDH2 | DSC3 rs2542729              
BTAF1 rs2792022              
NFKB1 rs28362491              
MYLK rs28497577              
ACVR1B rs2854464              
(intergenic) rs2854744              
RBPMS rs2979481              
CREBBP rs3025684              
TOM1L2 rs3183702              
LPL rs320              
CHRM2 rs324640              
LPL rs328              
RYR2 rs34967813              
NUAK1 rs3741886              
ATP1B1 rs3766031              
ATP1B1 rs3766044              
NRP2 rs3770991              
PDK4 rs3779478              
GRHL1 rs3791749              
EPAS1 rs4035887              
TUSC1 rs4246861              
PPARA rs4253778              
CPVL rs4257918              
APOE rs429358              
PHF2 rs4498613              
(intergenic) rs4522375              
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COMT rs4680              
PIWIL1 rs4759659              
ADD1 rs4961              
LRP5 rs4988300              
ADRB3 rs4994              
TYMS rs502396              
AGT rs5050              
(intergenic) rs5082              
EDN1 rs5370              
GNB3 rs5443              
NTRK2 rs615189              
LRP5 rs634008              
YWHAQ rs6432018              
RTP1 rs6444210              
SVIL rs6481619              
GABARAPL2 rs6564267              
UST rs6570913              
(intergenic) rs659366              
UCP2 rs660339              
PON1 rs662              
APOA1-AS rs670              
p300 (EP300) rs67744457              
MIR538 rs6865159              
NRF1 rs6949152              
AGT rs699              
(intergenic) rs699947              
CETP rs708272              
GNAS rs7121              
IGF1 rs7136446              
TMX1 | 
FRMD6 rs7154161              
GABPB1 rs7181866              
CYP19A1 rs727479              
MIPEP rs7324557              
DEPDC6 rs7386139              
APOE rs7412              
C7orf74 rs7792872              
TCERG1l rs7893895              
NHLRC2 rs7901769              
PDE3A rs7964046              
GABPB1 rs8031031              
LOC100131241 rs8069419              
CKMM rs8111989              
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PRLHR rs8192524              
PPARGC1A rs8192678              
DRG2 rs854762              
DRG2 rs854813              
OR6N2 rs857838              
ALX4 rs903514              
MYLIP rs909562              
ESR1 rs9340799              
FOXQ1 rs9378283              
SLFN11 rs938298              
HDAC2 rs9488289              
RTP1 rs9869355              
RTP1 rs9872701              
FTO rs9930506              
ACE rs4646994              
 
Table S3: Raw Genotyping Data for the Completers 30-42 
Group B A A A A B A A B B B A A 
Gene(s) SNP ID 65 67 72 75 78 79 80 83 84 87 91 95 102 
FAT2 rs10072841              
MATN2 rs10099863              
PDK4 rs10247649              
TFEC rs10248479              
ADRB2 rs1042713              
ADRB2 rs1042714              
ENPP1 rs1044498              
TTN rs10497520              
PPP1CC rs1050587              
PPARD rs1053049              
CYP2D6 rs1065852              
PLA2G2A rs10732279              
HBB rs10768683              
(intergenic) rs10861553              
AMN1 rs11051548              
(intergenic) rs1107946              
(intergenic) rs11096663              
LEPR rs1137101              
NME7 rs1138486              
HIF1A rs11549465              
ID3 rs11574              
RNASE1 rs11622895              
 
66 | P a g e  
 
EPAS1 rs11689011              
(intergenic) rs11770725              
(intergenic) rs12079745              
DIO1 rs12095080              
(intergenic) rs12535708              
(intergenic) rs12535747              
GABPB1 rs12594956              
KCNH7 rs12613181              
TMEM195 rs12672644              
YWHAQ rs12692388              
API5 rs12789205              
CREBBP rs130021              
LOC100288831 rs13060995              
HDAC2 rs13212283              
LEP rs13245201              
(intergenic) rs1341439              
(intergenic) rs1349419              
STS rs13648              
LOC730100 rs1451462              
ANO4 rs1532723              
DIS3L rs1546570              
GPRIN3 rs1560488              
(intergenic) rs1570360              
NPY rs16139              
EPS1 rs17039192              
LOC100129278 rs17044554              
(intergenic) rs17231506              
TTC17 rs17508783              
AMPD1 rs17602729              
(intergenic) rs17782313              
(intergenic) rs1799768              
FABP2 rs1799883              
HFE rs1799945              
COL1A1 rs1800012              
CNTF rs1800169              
PPARA rs1800234              
TGFB1 rs1800470              
HFE rs1800562              
(intergenic) rs1800588              
(intergenic) rs1800629              
CETP rs1800775              
LOC541472 rs1800795              
UCP3 rs1800849              
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MTHFR rs1801131              
MTHFR rs1801133              
ADRB1 rs1801252              
ADRB1 rs1801253              
MTRR rs1801394              
MYOSTAIN rs1805086              
MTR rs1805087              
ACTN3 rs1815739              
SPATA17 rs1832544              
EPAS1 rs1867785              
PTPRT rs1885831              
MTHFD1 rs1950902              
LIPG rs2000813              
FTHFD rs2002287              
VEGFA rs2010963              
PPARD rs2016520              
p300 (EP300) rs20551              
GCH1 rs2057368              
NOS3 rs2070744              
RAB6A rs2140892              
IL15RA rs2228059              
VDR rs2228570              
ESR1 rs2234693              
H19 rs2251375              
REEP3 rs2252578              
CREB1 rs2253206              
DOCK2 rs2270895              
FTHFD rs2276731              
TFAM rs2306604              
LRP5 rs2306862              
HYDIN rs235987              
CREB1 rs2360969              
NRF1 rs2402970              
SLC22A3 rs2457571              
CDH2 | DSC3 rs2542729              
BTAF1 rs2792022              
NFKB1 rs28362491              
MYLK rs28497577              
ACVR1B rs2854464              
(intergenic) rs2854744              
RBPMS rs2979481              
CREBBP rs3025684              
TOM1L2 rs3183702              
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LPL rs320              
CHRM2 rs324640              
LPL rs328              
RYR2 rs34967813              
NUAK1 rs3741886              
ATP1B1 rs3766031              
ATP1B1 rs3766044              
NRP2 rs3770991              
PDK4 rs3779478              
GRHL1 rs3791749              
EPAS1 rs4035887              
TUSC1 rs4246861              
PPARA rs4253778              
CPVL rs4257918              
APOE rs429358              
PHF2 rs4498613              
(intergenic) rs4522375              
COMT rs4680              
PIWIL1 rs4759659              
ADD1 rs4961              
LRP5 rs4988300              
ADRB3 rs4994              
TYMS rs502396              
AGT rs5050              
(intergenic) rs5082              
EDN1 rs5370              
GNB3 rs5443              
NTRK2 rs615189              
LRP5 rs634008              
YWHAQ rs6432018              
RTP1 rs6444210              
SVIL rs6481619              
GABARAPL2 rs6564267              
UST rs6570913              
(intergenic) rs659366              
UCP2 rs660339              
PON1 rs662              
APOA1-AS rs670              
p300 (EP300) rs67744457              
MIR538 rs6865159              
NRF1 rs6949152              
AGT rs699              
(intergenic) rs699947              
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CETP rs708272              
GNAS rs7121              
IGF1 rs7136446              
TMX1 | 
FRMD6 rs7154161              
GABPB1 rs7181866              
CYP19A1 rs727479              
MIPEP rs7324557              
DEPDC6 rs7386139              
APOE rs7412              
C7orf74 rs7792872              
TCERG1l rs7893895              
NHLRC2 rs7901769              
PDE3A rs7964046              
GABPB1 rs8031031              
LOC100131241 rs8069419              
CKMM rs8111989              
PRLHR rs8192524              
PPARGC1A rs8192678              
DRG2 rs854762              
DRG2 rs854813              
OR6N2 rs857838              
ALX4 rs903514              
MYLIP rs909562              
ESR1 rs9340799              
FOXQ1 rs9378283              
SLFN11 rs938298              
HDAC2 rs9488289              
RTP1 rs9869355              
RTP1 rs9872701              
FTO rs9930506              
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Table S4: SNPs Associated with Aerobic Capacity  
SNP ID Gene(s) Hetero Beneficial Reference 
rs10497520 TTN C/T T (Stebbings GK, 2018) 
rs1053049 PPARD C/T C (Ildus I. Ahmetov, 2015) 
rs10768683 HBB C/G G (Maffulli, 2013) 
rs11051548 AMN1 G/A A (Yoo J, 2016) 
rs11096663 PUM2 | RHOB A/G A (Yoo J, 2016) 
rs11574 ID3 C/T T (Timmons, 2009) 
rs12594956 GABPB1 (NRF2) A/C A (He Z, 2007) 
rs12613181 KCNH7 C/T C (Yoo J, 2016) 
rs13060995 SRGAP3 | LOC100288831 A/G A (Yoo J, 2016) 
rs1451462 LOC730100 | ASB3 C/T C (Yoo J, 2016) 
rs1546570 DIS3L A/C A (Timmons, 2009) 
rs1570360 (intergenic) A/G A or G* (Prior SJ, 2006) 
rs1799945 HFE C/G C/G (Grealy, 2015) 
rs1800629 (intergenic) A/G A (Del Coso J, 2017) 
rs1800795 LOC541472 C/G G (Del Coso J, 2017) 
rs2010963 VEGFA C/G C or G* (Prior SJ, 2006) 
rs2016520 PPARD C/T C (Maciejewska-karlowska, 2013) 
rs2251375 H19 A/C A (Timmons, 2009) 
rs2402970 NRF1 C/T C (He Z, 2007) 
rs2457571 SLC22A3 C/T T (Timmons, 2009) 
rs2542729 CDH2 | DSC3 C/T C (Yoo J, 2016) 
rs2792022 BTAF1 C/T C (Timmons, 2009) 
rs28497577 MYLK G/T T (Del Coso J, 2017) 
rs3770991 NRP2 A/G A (Timmons, 2009) 
rs4257918 CPVL A/G A (Timmons, 2009) 
rs6481619 SVIL A/C C (Timmons, 2009) 
rs6570913 UST A/G A (Yoo J, 2016) 
rs6949152 NRF1 A/G A (He Z, 2007) 
rs699947 (intergenic) A/C A or C* (Prior SJ, 2006) 
rs7181866 GABPB1 (NRF2) A/G G (He Z, 2007) 
rs7324557 MIPEP A/G A (Timmons, 2009) 
rs7386139 DEPDC6 A/G G (Timmons, 2009) 
rs8031031 GABPB1 (NRF2) C/T T (He Z, 2007) 
rs8111989 CKMM C/T T (Chen, 2017) 
rs8192678 PPARGC1A C/T C (Calvo JA, 2008) 
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Table S5: SNPs Associated with Physical Strength/Response to Training 
SNP ID Gene(s) Hetero Beneficial Reference 
rs10072841 FAT2 C/T C (Yoo J, 2016) 
rs1050587 PPP1CC C/T C (Windelinckx A, 2011) 
rs10861553 (intergenic) G/T T (Windelinckx A, 2011) 
rs1137101 LEPR A/G G (Quinton, 2001) 
rs11549465 HIF1A C/T C (Eynon N, 2010) 
rs12095080 DIO1 A/G T (Peeters RP1, 2005) 
rs1341439 SLC10A2 | DAOA C/T C (Yoo J, 2016) 
rs16139 NPY C/T C (Kallio J, 2001) 
rs17044554 LOC100129278 | KLHL29 G/T G (Yoo J, 2016) 
rs1800012 COL1A1 A/C C (Baumert, 2018) 
rs1800169 CNTF A/G A (Conwit RA, 2005) 
rs1805086 MYOSTAIN (GDF-8) C/T C (Catalina Santiago, 2011) 
rs1867785 EPAS1 A/G G (Henderson J., 2005) 
rs2228059 IL15RA G/T G (Bruneau Jr M, 2018) 
rs2306604 TFAM A/G A (Maruszak A1, 2014) 
rs3741886 NUAK1 A/C C (Windelinckx A, 2011) 
rs4035887 EPAS1 A/G G (Sarah Voisin, 2016) 
rs4253778 PPARA C/G C (Stastny P, 2019) 
rs4522375 NDN | PWRN2 C/T C (Yoo J, 2016) 
rs4988300 LRP5 G/T G (Kim HJ, 2018) 
rs5443 GNB3 C/T T (Grove ML, 2007) 
rs6564267 GABARAPL2 G/T G (Yoo J, 2016) 
rs660339 UCP2 A/G A (Kim HJ, 2018) 
rs7136446 IGF1 C/T C (Kostek MC, 2005) 
rs7154161 TMX1 | FRMD6 C/T C (Yoo J, 2016) 
rs7901769 NHLRC2 (PPP1CC) A/G A (Windelinckx A, 2011) 
rs11689011 EPAS1 C/T C (Henderson J., 2005) 
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Table S6: SNPs Associated with Cardiovascular Health 
SNP ID Gene(s) Hetero Beneficial Reference 
rs10099863 MATN2 A/C A (Rankinen T S. Y., 2012) 
rs10248479 TFEC G/T G (Rankinen T S. Y., 2012) 
rs1065852 CYP2D6 A/G G (Zateyshchikov DA, 2007) 
rs10732279 PLA2G2A C/T C (Rankinen T S. Y., 2012) 
rs1138486 NME7 C/T T (Chang YP1, 2007) 
rs11622895 RNASE1 C/T T (Rankinen T S. Y., 2012) 
rs12079745 (intergenic) A/G A (Prasad MK, 8(10): e76290) 
rs12672644 TMEM195 C/T T (Rankinen T S. Y., 2012) 
rs12692388 YWHAQ C/T T (Rankinen T S. Y., 2012) 
rs12789205 API5 G/T T (Rankinen T S. Y., 2012) 
rs1560488 GPRIN3 C/T T (Rankinen T S. Y., 2012) 
rs17508783 TTC17 A/G G (Rankinen T S. Y., 2012) 
rs17602729 AMPD1 A/G G (Rico-Sanz J, 2003) 
rs1800470 TGFB1 A/G A (Rivera MA, 2001) 
rs1800562 HFE G/A A (Sørensen E, 2019) 
rs1800775 CETP A/C C (Wang, 2014) 
rs1801252 ADRB1 A/G G (Pacanowski MA, 2008) 
rs1801253 ADRB1 C/G C (Pacanowski MA, 2008) 
rs1805087 MTR A/G G (Deng, 2019) 
rs1832544 SPATA17 A/G G (Rankinen T S. Y., 2012) 
rs1885831 PTPRT A/G G (Rankinen T S. Y., 2012) 
rs1950902 MTHFD1 A/G G (Wernimont, 2011) 
rs2057368 GCH1 A/G A (Rankinen T S. Y., 2012) 
rs2070744 NOS3 C/T T (Gamil, 2017) 
rs2140892 RAB6A A/G A (Rankinen T S. Y., 2012) 
rs2252578 REEP3 C/T C (Rankinen T S. Y., 2012) 
rs2253206 CREB1 A/G G (Rankinen T S. Y., 2012) 
rs2270895 DOCK2 A/G G (Rankinen T S. Y., 2012) 
rs235987 HYDIN C/T T (Rankinen T S. Y., 2012) 
rs2360969 CREB1 C/T T (Rankinen T S. Y., 2012) 
rs28362491 NFKB1 */ATTG ATTG (Park JY, 2007) 
rs2979481 RBPMS C/T C (Rankinen T S. Y., 2012) 
rs3183702 TOM1L2 A/G G (Rankinen T S. Y., 2012) 
rs320 LPL G/T G (Shatwan, 2018) 
rs324640 CHRM2 A/G A (Hautala AJ, 2006) 
rs34967813 RYR2 A/G G (Galati F, 2016) 
rs3766031 ATP1B1 C/T T (Chang YP1, 2007) 
rs3766044 ATP1B1 A/G G (Chang YP1, 2007) 
rs3791749 GRHL1 C/T C (Rankinen T S. Y., 2012) 
rs4246861 TUSC1 C/T C (Rankinen T S. Y., 2012) 
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rs4498613 PHF2 A/C C (Rankinen T S. Y., 2012) 
rs4680 COMT A/G A (Ge L, 2015) 
rs4759659 PIWIL1 A/G A (Rankinen T S. Y., 2012) 
rs4961 ADD1 G/T G (Sousa AC, 2017) 
rs502396 TYMS C/T T (Wernimont SM, 2012) 
rs5050 AGT G/T T (Purkait P, 2017) 
rs5370 EDN1 G/T G (Rankinen T C. T., 2007) 
rs615189 NTRK2 C/T C (Rankinen T S. Y., 2012) 
rs6432018 YWHAQ A/C A (Rankinen T S. Y., 2012) 
rs6444210 RTP1 C/T C (Rankinen T S. Y., 2012) 
rs659366 (intergenic) C/T T (Sun H, 2018) 
rs6865159 MIR538 C/T C (Rankinen T S. Y., 2012) 
rs699 AGT A/G G (Takeuchi F, 2012) 
rs7121 GNAS C/T C (Nieminen T, 2006) 
rs7412 APOE C/T C (Hagberg JM, 1999) 
rs7792872 C7orf74 C/T T (Rankinen T S. Y., 2012) 
rs7893895 TCERG1l C/T C (Rankinen T S. Y., 2012) 
rs7964046 PDE3A C/T T (Rankinen T S. Y., 2012) 
rs8069419 LOC100131241 A/C A (Rankinen T S. Y., 2012) 
rs8192524 PRLHR A/G A (Franks PW, 2004) 
rs854762 DRG2 A/G A (Rankinen T S. Y., 2012) 
rs854813 DRG2 T/C T (Rankinen T S. Y., 2012) 
rs857838 OR6N2 A/C A (Rankinen T S. Y., 2012) 
rs903514 ALX4 A/G A (Rankinen T S. Y., 2012) 
rs909562 MYLIP A/G G (Rankinen T S. Y., 2012) 
rs9378283 FOXQ1 A/G G (Rankinen T S. Y., 2012) 
rs938298 SLFN11 C/T T (Rankinen T S. Y., 2012) 
rs9869355 RTP1 C/T C (Rankinen T S. Y., 2012) 
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Table S7: SNPs Associated with Increased BMI/Obesity  
SNP ID Gene(s) Hetero Beneficial Reference 
rs10247649 PDK4 A/G A (Strachan DP, 2007) 
rs1042713 ADRB2 A/G A (Wolfarth B., 2000) 
rs1042714 ADRB2 C/G C (Gjesing AP1, 2007) 
rs1044498 ENPP1 A/C A (Pizzuti, 2008) 
rs11770725 (intergenic) C/T T (Jiang Y1, 2004) 
rs12535708 (intergenic) A/C A (Jiang Y1, 2004) 
rs12535747 (intergenic) A/C A (Jiang Y1, 2004) 
rs13245201 LEP A/G G (Jiang Y1, 2004) 
rs1349419 (intergenic) A/G A (Jiang Y1, 2004) 
rs13648 STS A/G G (Riechman SE, 2004) 
rs17231506 (intergenic) C/T C (Spielmann N, 2007) 
rs17782313 (intergenic) C/T T (Loos, 2008) 
rs1799883 FABP2 C/T C (Hancock AM, 2018) 
rs1800234 PPARA C/T T (Sabo, 2017) 
rs1800588 (intergenic) C/T C (Teran-Garcia M, 2005) 
rs1800849 UCP3 A/G G (Longo UG, 2010) 
rs1801394 MTRR A/G G (Bokor S, 2011) 
rs2000813 LIPG C/T C (Halverstadt A, 2003) 
rs2228570 VDR A/G G (Micheli ML, 2011) 
rs2854744 (intergenic) G/T G (Huuskonen A, 2011) 
rs328 LPL C/G C (Zhang S, 2015) 
rs3779478 PDK4 A/G G (Moon SS, 2012) 
rs429358 APOE C/T C or T* (Hagberg JM, 1999) 
rs4994 ADRB3 A/G A (Sakane N, 1997) 
rs5082 (intergenic) A/G T (Pisciotta L, 2003) 
rs634008 LRP5 C/T C (Guo, 2006) 
rs662 PON1 C/T C (Senti M, 2000) 
rs670 APOA1-AS G/A G (Ruano G, 2006) 
rs708272 CETP A/G G (Campos Y, 2002) 
rs9930506 FTO A/G A (Scuteri A, 2007) 
* Either allele within a specific haplotype with other SNPs can be beneficial 
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Table S8: SNPs Associated with Endurance and Strength 
SNP ID Gene(s) Hetero Beneficial Reference 
rs1815739 ACTN3 T/C T or C (Yang N., 2003) 
rs4646994 ACE D/I I or D (Bigham, 2008) 
 
Table S9: SNPs associated with Other Aspects of Physical Fitness  
SNP ID Gene(s) Hetero Beneficial Reference 
rs1107946 (intergenic) A/C A (Stewart TL, 2006) 
rs1532723 ANO4 C/T T (Tian Y, 2012) 
rs17039192 EPS1 C/T T (Saito, 2010) 
rs1799768 (intergenic)  -/G G (Yang, 2019) 
rs2234693 ESR1 C/T C (Tobias, 2007) 
rs2306862 LRP5 C/T C (Kiel, 2007) 
rs727479 CYP19A1 A/C C (Ellis, 2001) 
rs9340799 ESR1 A/G G (Tobias, 2007) 
 
Table S10: SNPs Associated with Epigenetic Modifiers 
SNP ID Gene(s) Hetero Beneficial Reference 
rs130021 CREBBP A/G n/a (Kumar D, 2011) 
rs13212283 HDAC2 A/G n/a (Jennifer Jurkin, 2011) 
rs1801131 MTHFR G/T n/a (Castro, 2004) 
rs1801133 MTHFR G/A n/a (Castro, 2004) 
rs2002287 FTHFD (ALDH1L1) A/G n/a (Stover, 2012) 
rs20551 p300 (EP300) A/G n/a (Jiao Li, 2017) 
rs2276731 FTHFD (ALDH1L1) C/T n/a (Min-Ae Song, 2016) 
rs3025684 CREBBP A/G n/a (Kumar D, 2011) 
rs67744457 p300 (EP300) GAA/* n/a (Jiao Li, 2017) 
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Table S11: ANOVA Analysis predictive SNPs for Anaerobic Peak Power % Change 0-12 Weeks  
SNP ID Performance Significance  
rs10248479 AP (Anaerobic Peak Power) % Change 0-12 weeks p= 0.0002 
rs1053049 AP (Anaerobic Peak Power) % Change 0-12 weeks p= 0.0500 
rs1138486 AP (Anaerobic Peak Power) % Change 0-12 weeks p= 0.0073 
rs11689011 AP (Anaerobic Peak Power) % Change 0-12 weeks p= 0.0364 
rs12079745 AP (Anaerobic Peak Power) % Change 0-12 weeks p= 0.0073 
rs1800562 AP (Anaerobic Peak Power) % Change 0-12 weeks p= 0.0009 
rs1801131 AP (Anaerobic Peak Power) % Change 0-12 weeks p= 0.0193 
rs1867785 AP (Anaerobic Peak Power) % Change 0-12 weeks p= 0.0257 
rs2057368 AP (Anaerobic Peak Power) % Change 0-12 weeks p= 0.0111 
rs28362491 AP (Anaerobic Peak Power) % Change 0-12 weeks p= 0.0478 
rs4961 AP (Anaerobic Peak Power) % Change 0-12 weeks p= 0.0023 
rs6432018 AP (Anaerobic Peak Power) % Change 0-12 weeks p= 0.0239 
rs7181866 AP (Anaerobic Peak Power) % Change 0-12 weeks p= 0.0062 
rs7154161 AP (Anaerobic Peak Power) % Change 0-12 weeks p= 0.0350 
rs7792872 AP (Anaerobic Peak Power) % Change 0-12 weeks p= 0.0355 
rs903514 AP (Anaerobic Peak Power) % Change 0-12 weeks p= 0.0424 
 
Table S12: ANOVA Analysis predictive SNPs for Relative Peak Power % Change 0-12 Weeks 
SNP ID Performance Significance  
rs10248479 RP (Relative Peak Power) % Change 0-12 weeks p= 0.0002 
rs1138486 RP (Relative Peak Power) % Change 0-12 weeks p= 0.0083 
rs11689011 RP (Relative Peak Power) % Change 0-12 weeks p= 0.0264 
rs12079745 RP (Relative Peak Power) % Change 0-12 weeks p= 0.0083 
rs1800562 RP (Relative Peak Power) % Change 0-12 weeks p= 0.0365 
rs1801131 RP (Relative Peak Power) % Change 0-12 weeks p= 0.0385 
rs1867785 RP (Relative Peak Power) % Change 0-12 weeks p= 0.0169 
rs2057368 RP (Relative Peak Power) % Change 0-12 weeks p= 0.0065 
rs28362491 RP (Relative Peak Power) % Change 0-12 weeks p= 0.0418 
rs4961 RP (Relative Peak Power) % Change 0-12 weeks p= 0.0028 
rs6432018 RP (Relative Peak Power) % Change 0-12 weeks p= 0.0236 
rs7181866 RP (Relative Peak Power) % Change 0-12 weeks p= 0.0073 
rs7154161 RP (Relative Peak Power) % Change 0-12 weeks p= 0.0413 
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Table S13: ANOVA Analysis predictive SNPs for Chest Press % Change 0-12 Weeks 
SNP ID Performance Significance  
rs12594956 Chest Press % Change 0-12 weeks p= 0.0375 
rs17044554 Chest Press % Change 0-12 weeks p= 0.0442 
rs1805087 Chest Press % Change 0-12 weeks p= 0.0474 
rs1805086 Chest Press % Change 0-12 weeks p= 0.0455 
rs1885831 Chest Press % Change 0-12 weeks p= 0.0474 
rs2002287 Chest Press % Change 0-12 weeks p= 0.0233 
rs2979481 Chest Press % Change 0-12 weeks p= 0.0029 
rs2854464 Chest Press % Change 0-12 weeks p= 0.0124 
rs320 Chest Press % Change 0-12 weeks p= 0.0341 
rs3779478 Chest Press % Change 0-12 weeks p= 0.0294 
rs4246861 Chest Press % Change 0-12 weeks p= 0.0084 
rs4253778 Chest Press % Change 0-12 weeks p= 0.0264 
 
Table S14: ANOVA Analysis predictive SNPs for Knee Extension % Change 0-12 Weeks 
SNP ID Performance Significance  
rs10072841 Knee Ext. % Change 0-12 weeks p= 0.0373 
rs12613181 Knee Ext. % Change 0-12 weeks p= 0.0407 
rs1546570 Knee Ext. % Change 0-12 weeks p= 0.0020 
rs1800629 Knee Ext. % Change 0-12 weeks p= 0.0263 
rs1800470 Knee Ext. % Change 0-12 weeks p= 0.0226 
rs1832544 Knee Ext. % Change 0-12 weeks p= 0.0025 
rs324640 Knee Ext. % Change 0-12 weeks p= 0.0289 
rs34967813 Knee Ext. % Change 0-12 weeks p= 0.0225 
rs4257918 Knee Ext. % Change 0-12 weeks p= 0.0123 
rs4646994 Knee Ext. % Change 0-12 weeks p= 0.0076 
rs6570913 Knee Ext. % Change 0-12 weeks p= 0.0445 
rs699 Knee Ext. % Change 0-12 weeks p= 0.0300 
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Table S15: ANOVA Analysis predictive SNPs for Overhead Press % Change 0-12 Weeks 
SNP ID Performance Significance  
rs10732279 Overhead Press % Change 0-12 weeks p= 0.0038 
rs1107946 Overhead Press % Change 0-12 weeks p= 0.0034 
rs130021 Overhead Press % Change 0-12 weeks p= 0.0110 
rs1560488 Overhead Press % Change 0-12 weeks p= 0.0290 
rs17602729 Overhead Press % Change 0-12 weeks p= 0.0172 
rs2070744 Overhead Press % Change 0-12 weeks p= 0.0031 
rs2360969 Overhead Press % Change 0-12 weeks p= 0.0074 
 
Table S16: ANOVA Analysis predictive SNPs for Knee Peak Power % Change 0-12 Weeks 
SNP ID Performance Significance  
rs12095080 Knee Peak Power PP % Change 0-12 weeks p= 0.0437 
rs130021 Knee Peak Power PP % Change 0-12 weeks p= 0.0471 
rs1560488 Knee Peak Power PP % Change 0-12 weeks p= 0.0321 
rs1799768 Knee Peak Power PP % Change 0-12 weeks p= 0.0132 
rs2070744 Knee Peak Power PP % Change 0-12 weeks p= 0.0295 
rs2140892 Knee Peak Power PP % Change 0-12 weeks p= 0.0027 
rs28362491 Knee Peak Power PP % Change 0-12 weeks p= 0.0103 
rs2457571 Knee Peak Power PP % Change 0-12 weeks p= 0.0248 
rs660339 Knee Peak Power PP % Change 0-12 weeks p= 0.0019 
rs659366 Knee Peak Power PP % Change 0-12 weeks p= 0.0003 
rs7412 Knee Peak Power PP % Change 0-12 weeks p= 0.0054 
 
Table S17: ANOVA Analysis predictive SNPs for Lat Pull % Change 0-12 Weeks 
SNP ID Performance Significance  
rs10099863 Lat Pull % Change 0-12 weeks p= 0.0260 
rs11549465 Lat Pull % Change 0-12 weeks p= 0.0299 
rs1349419 Lat Pull % Change 0-12 weeks p= 0.0463 
rs1570360 Lat Pull % Change 0-12 weeks p= 0.0035 
rs2002287 Lat Pull % Change 0-12 weeks p= 0.0075 
rs2979481 Lat Pull % Change 0-12 weeks p= 0.0054 
rs320 Lat Pull % Change 0-12 weeks p= 0.0362 
rs502396 Lat Pull % Change 0-12 weeks p= 0.0163 
rs7121 Lat Pull % Change 0-12 weeks p= 0.0356 
rs7792872 Lat Pull % Change 0-12 weeks p= 0.0011 
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Table S18: ANOVA Analysis predictive SNPs for Vertical Jump % Change 0-12 Weeks 
SNP ID Performance Significance  
rs10732279 Vertical Jump VJ % Change 0-12 weeks p= 0.0070 
rs1801253 Vertical Jump VJ % Change 0-12 weeks p= 0.0064 
rs1805087 Vertical Jump VJ % Change 0-12 weeks p= 0.0126 
rs2228059 Vertical Jump VJ % Change 0-12 weeks p= 0.0362 
rs4994 Vertical Jump VJ % Change 0-12 weeks p= 0.0001 
rs5082 Vertical Jump VJ % Change 0-12 weeks p= 0.0027 
rs615189 Vertical Jump VJ % Change 0-12 weeks p= 0.0196 
rs6444210 Vertical Jump VJ % Change 0-12 weeks p= 0.0261 
 
 
Table S19: ANOVA Analysis predictive SNPs for Squat % Change 0-12 Weeks 
SNP ID Performance Significance  
rs11622895 Squat % Change 0-12 weeks p= 0.0056 
rs1532723 Squat % Change 0-12 weeks p= ˂ 0.001 
rs1832544 Squat % Change 0-12 weeks p= 0.0476 
rs1885831 Squat % Change 0-12 weeks p= 0.0433 
rs2234693 Squat % Change 0-12 weeks p= 0.0057 
rs28362491 Squat % Change 0-12 weeks p= 0.0222 
rs324640 Squat % Change 0-12 weeks p= 0.0112 
rs4246861 Squat % Change 0-12 weeks p= 0.0143 
rs708272 Squat % Change 0-12 weeks p= 0.0410 
rs7412 Squat % Change 0-12 weeks p= 0.0311 
rs7964046 Squat % Change 0-12 weeks p= 0.0068 
rs8069419 Squat % Change 0-12 weeks p= 0.0427 
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Table S20: ANOVA Analysis predictive SNPs for VO2max (ml/kg/min) % Change 0-12 Weeks 
SNP ID Performance Significance  
rs17044554 VO2 Peak (ml/kg/min) % Change 0-12 weeks p= 0.0111 
rs1799768 VO2 Peak (ml/kg/min) % Change 0-12 weeks p= 0.0406 
rs1805087 VO2 Peak (ml/kg/min) % Change 0-12 weeks p= 0.0279 
rs1805086 VO2 Peak (ml/kg/min) % Change 0-12 weeks p= 0.0079 
rs2402970 VO2 Peak (ml/kg/min) % Change 0-12 weeks p= 0.0006 
rs2854744 VO2 Peak (ml/kg/min) % Change 0-12 weeks p= 0.0121 
rs3770991 VO2 Peak (ml/kg/min) % Change 0-12 weeks p= 0.0298 
rs4961 VO2 Peak (ml/kg/min) % Change 0-12 weeks p= 0.0072 
rs502396 VO2 Peak (ml/kg/min) % Change 0-12 weeks p= 0.0077 
rs660339 VO2 Peak (ml/kg/min) % Change 0-12 weeks p= 0.0274 
rs6949152 VO2 Peak (ml/kg/min) % Change 0-12 weeks p= 0.0087 
rs699947 VO2 Peak (ml/kg/min) % Change 0-12 weeks p= 0.0463 
rs7792872 VO2 Peak (ml/kg/min) % Change 0-12 weeks p= 0.0429 
rs857838 VO2 Peak (ml/kg/min) % Change 0-12 weeks p= 0.0015 
 
Table S21: ANOVA Analysis predictive SNPs for Arm Lean Mass LM Change 0-12 Weeks (grams)  
SNP ID Performance Significance  
rs1560488 Arm Lean Mass LM Change 0-12 weeks (grams) p= 0.0067 
rs1801133 Arm Lean Mass LM Change 0-12 weeks (grams) p= 0.0425 
rs2276731 Arm Lean Mass LM Change 0-12 weeks (grams) p= 0.0101 
rs2457571 Arm Lean Mass LM Change 0-12 weeks (grams) p= 0.0149 
rs2854744 Arm Lean Mass LM Change 0-12 weeks (grams) p= 0.0234 
rs4759659 Arm Lean Mass LM Change 0-12 weeks (grams) p= 0.0424 
rs7792872 Arm Lean Mass LM Change 0-12 weeks (grams) p= 0.0075 
 
Table S22: ANOVA Analysis predictive SNPs for Max Voluntary Contraction % Change 0-12 Weeks 
SNP ID Performance Significance  
rs17602729 MVC % Change 0-12 weeks p= 0.0124 
rs2542729 MVC % Change 0-12 weeks p= 0.0432 
rs324640 MVC % Change 0-12 weeks p= 0.0431 
rs3741886 MVC % Change 0-12 weeks p= 0.0141 
rs708272 MVC % Change 0-12 weeks p= 0.0150 
rs727479 MVC % Change 0-12 weeks p= 0.0074 
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Table S23: ANOVA Analysis predictive SNPs for Bodyfat % Change 0-12 Weeks 
SNP ID Performance Significance  
rs12672644 Bodyfat Change 0-12 weeks p= 0.0316 
rs1799883 Bodyfat Change 0-12 weeks p= 0.0223 
rs1800012 Bodyfat Change 0-12 weeks p= 0.0072 
rs1801131 Bodyfat Change 0-12 weeks p= 0.0089 
rs2228570 Bodyfat Change 0-12 weeks p= 0.0387 
rs2792022 Bodyfat Change 0-12 weeks p= 0.0402 
rs328 Bodyfat Change 0-12 weeks p= 0.0008 
rs3770991 Bodyfat Change 0-12 weeks p= 0.0364 
rs3791749 Bodyfat Change 0-12 weeks p= 0.0489 
rs4257918 Bodyfat Change 0-12 weeks p= 0.0427 
rs615189 Bodyfat Change 0-12 weeks p= 0.0218 
rs7324557 Bodyfat Change 0-12 weeks p= 0.0340 
rs8069419 Bodyfat Change 0-12 weeks p= 0.0037 
rs903514 Bodyfat Change 0-12 weeks p= 0.0117 
 
Table S24: ANOVA Analysis predictive SNPs for Thigh Lean Mass, Both Legs, Change 0-12 Weeks (grams) 
SNP ID Performance Significance  
rs10072841 Thigh Lean Mass; Both Legs TLM Change 0-12 weeks (grams) p= 0.0380 
rs11689011 Thigh Lean Mass; Both Legs TLM Change 0-12 weeks (grams) p= 0.0299 
rs1532723 Thigh Lean Mass; Both Legs TLM Change 0-12 weeks (grams) p= 0.0038 
rs1546570 Thigh Lean Mass; Both Legs TLM Change 0-12 weeks (grams) p= 0.0149 
rs1801133 Thigh Lean Mass; Both Legs TLM Change 0-12 weeks (grams) p= 0.0175 
rs1867785 Thigh Lean Mass; Both Legs TLM Change 0-12 weeks (grams) p= 0.0311 
rs3025684 Thigh Lean Mass; Both Legs TLM Change 0-12 weeks (grams) p= 0.0077 
rs3791749 Thigh Lean Mass; Both Legs TLM Change 0-12 weeks (grams) p= 0.0115 
rs4680 Thigh Lean Mass; Both Legs TLM Change 0-12 weeks (grams) p= 0.0459 
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Table S25: ANOVA Analysis predictive SNPs for Visceral Fat Mass Change 0-12 Weeks (grams) 
SNP ID Performance Significance  
rs1042713 Visceral Fat Mass Change 0-12 weeks (grams) p= 0.0374 
rs130021 Visceral Fat Mass Change 0-12 weeks (grams) p= 0.0452 
rs17231506 Visceral Fat Mass Change 0-12 weeks (grams) p= 0.0203 
rs17602729 Visceral Fat Mass Change 0-12 weeks (grams) p= 0.0224 
rs1800775 Visceral Fat Mass Change 0-12 weeks (grams) p= 0.0275 
rs1801252 Visceral Fat Mass Change 0-12 weeks (grams) p= 0.0420 
rs34967813 Visceral Fat Mass Change 0-12 weeks (grams) p= 0.0285 
rs3791749 Visceral Fat Mass Change 0-12 weeks (grams) p= 0.0385 
rs4646994 Visceral Fat Mass Change 0-12 weeks (grams) p= 0.0273 
rs4522375 Visceral Fat Mass Change 0-12 weeks (grams) p= 0.0008 
rs4759659 Visceral Fat Mass Change 0-12 weeks (grams) p= 0.0345 
rs708272 Visceral Fat Mass Change 0-12 weeks (grams) p= 0.0200 
rs7324557 Visceral Fat Mass Change 0-12 weeks (grams) p= 0.0236 
rs7181866 Visceral Fat Mass Change 0-12 weeks (grams) p= 0.0092 
rs7901769 Visceral Fat Mass Change 0-12 weeks (grams) p= 0.0005 
rs938298 Visceral Fat Mass Change 0-12 weeks (grams) p= 0.0029 
rs9488289 Visceral Fat Mass Change 0-12 weeks (grams) p= 0.0287 
 
Table S26: ANOVA Analysis predictive SNPs for Total Lean Mass Change 0-12 Weeks (grams) 
SNP ID Performance Significance  
rs11689011 Total Lean Mass LM Change 0-12 weeks (grams) p= 0.0347 
rs11622895 Total Lean Mass LM Change 0-12 weeks (grams) p= 0.0161 
rs1799945 Total Lean Mass LM Change 0-12 weeks (grams) p= 0.0221 
rs1801133 Total Lean Mass LM Change 0-12 weeks (grams) p= 0.0025 
rs1867785 Total Lean Mass LM Change 0-12 weeks (grams) p= 0.0315 
rs2252578 Total Lean Mass LM Change 0-12 weeks (grams) p= 0.0460 
rs3025684 Total Lean Mass LM Change 0-12 weeks (grams) p= 0.0409 
rs3791749 Total Lean Mass LM Change 0-12 weeks (grams) p= 0.0464 
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